ArticleHuman cell2014
miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin.
Article in Human cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Retraction: QKI5mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis.Oncotarget · 2026Article
- miR-137: a potential therapeutic target for lung cancer.Frontiers in cell and developmental biology · 2024Review
- Article
- Regulation of Oncogenic Targets by the Tumor-SuppressiveBiomedicines · 2020Article
- Identification and Analysis of Dysfunctional Genes and Pathways in CD8Frontiers in genetics · 2020Article
- MiR-137 promotes anoikis through modulating the AKT signaling pathways in Pancreatic Cancer.Journal of Cancer · 2020Article
- Paxillin family of focal adhesion adaptor proteins and regulation of cancer cell invasion.International review of cell and molecular biology · 2020Article
- Aberrant MicroRNAomics in Pulmonary Complications: Implications in Lung Health and Diseases.Molecular therapy. Nucleic acids · 2019Review
- Long noncoding RNA PXN-AS1-L promotes non-small cell lung cancer progression via regulating PXN.Cancer cell international · 2019Article
- Aberrant microRNA-137 promoter methylation is associated with lymph node metastasis and poor clinical outcomes in non-small cell lung cancer.Oncology letters · 2018Article
- miR-137 inhibits the proliferation of human non-small cell lung cancer cells by targeting SRC3.Oncology letters · 2017Article
- Paxillin: a crossroad in pathological cell migration.Journal of hematology & oncology · 2017Review
- MiR-137: an important player in neural development and neoplastic transformation.Molecular psychiatry · 2017Review
- microRNA-137 is downregulated in thyroid cancer and inhibits proliferation and invasion by targeting EGFR.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- miR-137 acts as a tumor suppressor in astrocytoma by targeting RASGRF1.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- MicroRNA Regulation of Endothelial Junction Proteins and Clinical Consequence.Mediators of inflammation · 2016Review
- miR-137 suppresses the invasion and procedure of EMT of human breast cancer cell line MCF-7 through targeting CtBP1.Human cell · 2016Article
- Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma.American journal of cancer research · 2016Article
- MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2.Experimental & molecular medicine · 2014Article
- microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human lung cancer is the leading cause of cancer motility worldwide, with nearly 1.4 million deaths each year, among which non-small cell lung cancer (NSCLC) accounts for almost 85% of this disease. The discovery of microRNAs (miRNAs) provides a new avenue for NSCLC diagnostic and treatment regiments. Currently, a large number of miRNAs have been reported to be associated with the progression of NSCLC, among which serum miR-137 has been examined to be down-regulated in NSCLC patients. However, the function of miR-137 on NSCLC cells migration and invasion and the relative mechanisms were less known. Here, we found that ectopic expression of miR-137 could inhibit cell proliferation, induce cell apoptosis, and suppress cell migration and invasion in NSCLC cell line A549. Moreover, we found that paxillin (PXN) was a target gene of miR-137 in NSCLC cells and restored expression of PXN abolished the miR-137-mediated suppression of cell migration and invasion. Taken together, our results showed that miR-137 acted as a tumor suppressor in NSCLC by targeting PXN, and it may provide novel diagnostic and therapeutic options for human NSCLC clinical operation in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.